# Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

> **NCT00031083** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 12 (—)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Oligoastrocytoma, Mixed
- Gliosarcoma

## Interventions

- **GENETIC:** Interferon-beta

## Key facts

- **NCT ID:** NCT00031083
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04-02
- **Primary completion:** —
- **Final completion:** 2003-10-10
- **Target enrollment:** 12 (—)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00031083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00031083, "Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00031083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*